ProShare Advisors LLC Buys 861 Shares of Glaukos Corporation $GKOS

ProShare Advisors LLC grew its stake in Glaukos Corporation (NYSE:GKOS) by 7.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,502 shares of the medical instruments supplier’s stock after purchasing an additional 861 shares during the period. ProShare Advisors LLC’s holdings in Glaukos were worth $1,291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Alliancebernstein L.P. lifted its stake in Glaukos by 56.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after purchasing an additional 461,386 shares during the last quarter. AustralianSuper Pty Ltd acquired a new position in shares of Glaukos during the second quarter worth $41,946,000. William Blair Investment Management LLC lifted its stake in shares of Glaukos by 52.4% in the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock valued at $117,347,000 after acquiring an additional 390,805 shares during the last quarter. Braidwell LP boosted its holdings in shares of Glaukos by 116.2% during the 1st quarter. Braidwell LP now owns 624,435 shares of the medical instruments supplier’s stock valued at $61,457,000 after acquiring an additional 335,559 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Glaukos during the 1st quarter worth $31,474,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GKOS has been the subject of several research reports. Zacks Research downgraded Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. William Blair raised Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. Needham & Company LLC raised their price objective on shares of Glaukos from $115.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Truist Financial set a $120.00 target price on shares of Glaukos in a report on Thursday, October 30th. Finally, BTIG Research upped their price target on shares of Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $119.08.

Glaukos Price Performance

Glaukos stock opened at $90.05 on Monday. The stock’s 50 day moving average is $84.10 and its 200 day moving average is $91.19. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71. The firm has a market cap of $5.17 billion, a P/E ratio of -58.48 and a beta of 0.81. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The company’s revenue was up 38.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.28) EPS. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.